Method Of Regulating Cell Metabolism Or Physiology Patents (Class 435/375)
-
Patent number: 11975024Abstract: The present invention relates to compositions comprising induced T regulatory cells (iTregs), methods of making the compositions, and methods of using the compositions for enhancing bone remodeling in the treatment of Osteogenesis Imperfecta (OI).Type: GrantFiled: December 17, 2018Date of Patent: May 7, 2024Assignee: MUSC Foundation for Research DevelopmentInventors: Meenal Mehrotra, In-Hong Kang, Uday Baliga
-
Patent number: 11976068Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.Type: GrantFiled: June 24, 2021Date of Patent: May 7, 2024Assignee: ONCOCEUTICS, INC.Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
-
Patent number: 11963957Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: December 7, 2020Date of Patent: April 23, 2024Assignees: Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc., Buck Institute for Research on AgingInventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Jan M. A. van Deursen, Darren J. Baker, Bennett G. Childs
-
Patent number: 11957707Abstract: Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.Type: GrantFiled: September 17, 2019Date of Patent: April 16, 2024Assignee: SYNEDGEN, INC.Inventors: Shenda M. Baker, William P. Wiesmann, Stacy Marie Townsend
-
Patent number: 11951211Abstract: A method for producing uniform-size liposomes is provided. The liposomes are coated with a sorting agent to yield a plurality of density-modified liposomes of different sizes. These liposomes are then separated using a densitometric method. The sorting agent includes both a density-modifying moiety and a targeting moiety.Type: GrantFiled: January 29, 2021Date of Patent: April 9, 2024Assignee: YALE UNIVERSITYInventors: Chenxiang Lin, Yang Yang
-
Patent number: 11952573Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of PHD2 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against PHD2 gene expression.Type: GrantFiled: April 1, 2022Date of Patent: April 9, 2024Assignee: Sirna Therapeutics, Inc.Inventors: Brandon Ason, Duncan Brown, Walter R. Strapps
-
Patent number: 11946072Abstract: Described herein are methods and culture medium, useful for inducing polarization in multipotent stem cells. Additionally, described herein are multipotent cells produced by the methods and culture medium of this disclosure that are useful therapeutic agents. Also described herein are extracellular vesicles and factors secreted by multipotent cells that are produced by the methods and culture medium of this disclosure that are useful as therapeutic agents.Type: GrantFiled: September 28, 2018Date of Patent: April 2, 2024Assignee: SanBio, Inc.Inventors: Aline M. Betancourt, Ruth S. Waterman, Thomas F. Isett
-
Patent number: 11944642Abstract: The present invention relates to mitochondrial compositions and therapeutic methods of using same. The invention discloses compositions of partially purified functional mitochondria and methods of using the compositions to treat conditions which benefit from increased mitochondrial function by administering the compositions to a subject in need thereof.Type: GrantFiled: March 30, 2020Date of Patent: April 2, 2024Assignee: Minovia Therapeutics Ltd.Inventors: Natalie Yivgi-Ohana, Uriel Halavee
-
Patent number: 11946046Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: GrantFiled: June 14, 2019Date of Patent: April 2, 2024Assignee: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Patent number: 11938191Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: May 1, 2020Date of Patent: March 26, 2024Assignee: GENEVANT SCIENCES GMBHInventors: Sean D. Monahan, Michael S. Declue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Patent number: 11931353Abstract: A method of preventing or treating a subject suffering from a flavivirus infection by administering an effective amount of berbamine or its analogue to the subject, berbamine has a structure of Formula (I), wherein the flavivirus infection is caused by Japanese encephalitis virus, Zika virus or Dengue virus. A method of inhibiting the entry of a flavivirus, an enterovirus and/or a lentivirus into host cells includes contacting the host cells with an effective amount of berbamine of its analogue, berbamine has a structure of Formula (I), wherein the flavivirus is Japanese encephalitis virus, Zika virus or Dengue virus.Type: GrantFiled: May 6, 2022Date of Patent: March 19, 2024Assignee: City University of Hong KongInventors: Jianbo Yue, Lihong Huang
-
Patent number: 11932855Abstract: Retrotransposons, operating though human-specific neurological pathways, can contribute to environment, lifestyle, and/or age-related neurodegeneration by disrupting functional mitochondrial populations within neurons. The mitochondrial disruption can occur through a number of retrotransposon-induced mechanisms that can influence the efficient and accurate transcription and/or translation of mitochondrial genes encoded in the nuclear genome, operating primarily through epigenetic processes. Alu element-related conformational changes (both subtle and major) of the outer and inner mitochondrial membrane pores can restrict or prevent the normal translocation of proteins (i.e., TOMM and TIMM complexes), ultimately contributing to mitochondrial stress, mitophagy, inflammation, and neuron and glial cell death.Type: GrantFiled: April 19, 2022Date of Patent: March 19, 2024Assignee: DUKE UNIVERSITYInventor: Peter Anthony Larsen
-
Patent number: 11926829Abstract: The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2.Type: GrantFiled: February 3, 2021Date of Patent: March 12, 2024Assignees: ASSOICATION INSTITUT DE MYOLOGIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Marc Bitoun, Delphine Trochet, Bernard Prudhon
-
Patent number: 11919967Abstract: An antibody or fragment thereof, against presenilin, and more specifically against the luminal loop 1 of presenilin, for use in the treatment of cancer, by way of administrating a therapeutically effective quantity of the antibody or a fragment thereof, or a pharmaceutical composition comprising thereof, to a subject who suffers from cancer.Type: GrantFiled: August 3, 2018Date of Patent: March 5, 2024Assignees: ALZHEIMUR 2012 S.L., FUNDACION UNIVERSITARIA SAN ANTONIO, IBSAL (INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANC, UNIVERSIDAD DE SALAMANCAInventors: Rogelio Gonzalez Sarmiento, Miguel Rodriguez Manotas, Javier Fernandez Mateos, Juan Carlos Gallar Ruiz, David Florenciano Gomez
-
Patent number: 11920134Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.Type: GrantFiled: April 13, 2020Date of Patent: March 5, 2024Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
-
Patent number: 11920132Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.Type: GrantFiled: January 8, 2021Date of Patent: March 5, 2024Assignee: ProQR Therapeutics II B.V.Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
-
Patent number: 11919937Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.Type: GrantFiled: January 9, 2019Date of Patent: March 5, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Jinsheng Weng, Kelsey Moriarty, Sattva S. Neelapu
-
Patent number: 11918555Abstract: The disclosure provides compositions and methods of treating diseases and conditions associated with phospholipase D (PLD) toxin. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester.Type: GrantFiled: December 16, 2021Date of Patent: March 5, 2024Assignee: NEW FRONTIER LABS, LLCInventors: Robert T. Streeper, Elzbieta Izbicka
-
Patent number: 11912789Abstract: The present invention is related to compositions and methods for activating Lck, including in vivo, in vitro and ex vivo uses.Type: GrantFiled: May 15, 2019Date of Patent: February 27, 2024Assignee: Interk Peptide Therapeutics LimitedInventor: Michael Valentine Agrez
-
Patent number: 11911358Abstract: The disclosure provides compositions and methods of inducing an analgesic effect. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester.Type: GrantFiled: December 16, 2021Date of Patent: February 27, 2024Inventors: Robert T. Streeper, Elzbieta Izbicka
-
Patent number: 11911403Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.Type: GrantFiled: October 26, 2020Date of Patent: February 27, 2024Assignee: Sarepta Therapeutics, Inc.Inventor: Dan V. Mourich
-
Patent number: 11911359Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.Type: GrantFiled: November 3, 2014Date of Patent: February 27, 2024Assignee: PDS Biotechnology CorporationInventors: Weihsu Chen, Weili Yan, Kenya Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
-
Patent number: 11905537Abstract: The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.Type: GrantFiled: August 3, 2018Date of Patent: February 20, 2024Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Nate Hathaway, Jian Jin, Kyle Butler, Anna Chiarella
-
Patent number: 11903968Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.Type: GrantFiled: July 20, 2018Date of Patent: February 20, 2024Assignee: CELLECTISInventors: Philippe Duchateau, Anne-Sophie Gautron, Laurent Poirot, Julien Valton
-
Patent number: 11905559Abstract: A high-resolution dual-beam counter propagating optical-tweezers instrument was designed that can measure forces at <1 pN and one nanometer distance at a temporal resolution of 25 ?s with high accuracy and precision. Using the high-resolution optical-tweezers, time-dependent conformational switching and structural rearrangements in a single-molecule of the guanine aptamer were identified that follow a modified induced-fit model, where guanine remodels multiple barriers and triggers the receptor conformation rapidly to synchronize with the elongating transcriptional machinery for controlling gene regulation.Type: GrantFiled: August 2, 2017Date of Patent: February 20, 2024Inventor: Maumita Mandal
-
Patent number: 11896713Abstract: A nanocarrier containing a combination of bioactive agents is provided. The nanocarrier allows for targeted delivery of the agents to cancer cells with minimized side effect.Type: GrantFiled: October 22, 2021Date of Patent: February 13, 2024Assignee: Rutgers, The State University of New JerseyInventors: Tamara Minko, Olga B. Garbuzenko
-
Patent number: 11891644Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.Type: GrantFiled: June 5, 2018Date of Patent: February 6, 2024Assignee: Seagen Inc.Inventors: Nicole Okeley, Jessica Field, Shyra Gardai, Ryan Heiser
-
Patent number: 11890286Abstract: Methods and compositions for treating cancer are disclosed.Type: GrantFiled: April 17, 2019Date of Patent: February 6, 2024Assignee: The University of ChicagoInventors: Ali Ekram Yesilkanal, Marsha Rosner
-
Patent number: 11891689Abstract: Fabricating a nanopore sensor includes depositing a first and second oxide layers on first and second sides of a sapphire substrate. The second oxide layer is patterned to form an etch mask having a mask opening in the second oxide layer. A crystalline orientation dependent wet anisotropic etch is performed on the second side of the sapphire substrate using the etch mask to form a cavity having sloped side walls through the sapphire substrate to yield an exposed portion of the first oxide layer, each of the sloped side walls being a crystalline facet aligned with a respective crystalline plane of the sapphire substrate. A silicon nitride layer is deposited on the first oxide layer. The exposed portion of the first oxide layer in the cavity is removed, thereby defining a silicon nitride membrane in the cavity. An opening is formed through the silicon nitride membrane.Type: GrantFiled: March 3, 2021Date of Patent: February 6, 2024Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: Chao Wang, Pengkun Xia
-
Patent number: 11893733Abstract: Systems and methods for predicting a patient response to various agents and/or combinations of agents using ex vivo dosing and imaging are disclosed. In one example, a method of determining treatment efficacy includes analyzing a solid cell culture over time, e.g., first and second responses to a solid cell culture to respective treatments may be compared to determine a treatment efficacy of each treatment. Systems and methods for applying the treatments to the cell culture and analyzing the cell culture and efficacy are disclosed.Type: GrantFiled: October 26, 2021Date of Patent: February 6, 2024Assignee: OUROTECH, INC.Inventors: Duleeka Nimantha Bandara Ranatunga, Eleonora Peerani, Gastón Agustín Primo, Zhi Yuan Lin, Sacha Hu, Aston Martin Crawley
-
Patent number: 11883438Abstract: It is an object to provide a technique useful for embryo transfer and development of reproductive medical care. Provided are a sperm activator containing a disrupted product of one or more cells selected from the group consisting of adipose tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord blood-derived stem cells as an active ingredient, and an artificial insemination method utilizing the same.Type: GrantFiled: August 23, 2017Date of Patent: January 30, 2024Assignees: National University Corporation Nagoya University, Gifu University, Gifu PrefectureInventors: Tokunori Yamamoto, Satoshi Suzuki, Yasuhito Funahashi, Yoshihisa Matsukawa, Momokazu Gotoh, Tomohiro Kitayama, Yoichiro Hoshino, Tetsuma Murase
-
Patent number: 11883391Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.Type: GrantFiled: March 31, 2021Date of Patent: January 30, 2024Assignee: CHEMOCENTRYX, INC.Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
-
Patent number: 11879155Abstract: Methods and compositions for characterizing a target polynucleotide, including, characterizing the sequence of the target polynucleotide, using the fractional translocation steps of the target polynucleotide's translocation through a pore.Type: GrantFiled: May 25, 2021Date of Patent: January 23, 2024Assignee: Illumina, Inc.Inventors: Eric Stava, Jens H. Gundlach, Jeffrey G. Mandell, Kevin L. Gunderson, Ian M. Derrington, Hosein Mohimani
-
Patent number: 11873511Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.Type: GrantFiled: October 19, 2017Date of Patent: January 16, 2024Assignee: CELLECTISInventors: Brian Busser, Philippe Duchateau, Alexandre Juillerat, Laurent Poirot, Julien Valton
-
Patent number: 11859205Abstract: Culture media, which contain albumin carrying a reduced amount of fatty acid, are useful for culturing stem cells.Type: GrantFiled: June 11, 2020Date of Patent: January 2, 2024Assignee: AJINOMOTO CO., INC.Inventors: Yoko Kuriyama, Sho Senda, Yumi Ando, Tomomi Yoshida, Haruna Sato, Daisuke Ejima, Takayoshi Fujii, Masayo Date, Manabu Kitazawa
-
Patent number: 11857958Abstract: A microfluidic cell culture chip which contains a central module comprising a central unit, which contains a support consisting of a non-resorbable membrane, a 3D nanostructured porous membrane, comprising at least one protuberance, and the 3D nanostructured porous membrane and that at least one protuberance being composed of materials suitable for the culture of two distinct cell types; a base, and the central unit being integrated in the base, and forming a whole with the base.Type: GrantFiled: May 11, 2017Date of Patent: January 2, 2024Assignee: UNIVERSITE GRENOBLE ALPESInventors: Donald Keith Martin, Nathalie Picollet-D'Hahan
-
Patent number: 11857809Abstract: The invention provides compositions featuring TRP-4 polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a cell type of interest, and methods for inducing the activation of the TRP-4 polypeptide in neurons and other cell types using ultrasound.Type: GrantFiled: September 23, 2020Date of Patent: January 2, 2024Assignee: Salk Institute for Biological StudiesInventors: Sreekanth H. Chalasani, Stuart Ibsen
-
Patent number: 11847780Abstract: Systems and methods for predicting a patient response to various agents and/or combinations of agents using ex vivo dosing and imaging are disclosed. In one example, a method of determining treatment efficacy includes analyzing a solid cell culture over time, e.g., first and second responses to a solid cell culture to respective treatments may be compared to determine a treatment efficacy of each treatment. Systems and methods for applying the treatments to the cell culture and analyzing the cell culture and efficacy are disclosed.Type: GrantFiled: October 26, 2021Date of Patent: December 19, 2023Assignee: OUROTECH, INC.Inventors: Duleeka Nimantha Bandara Ranatunga, Eleonora Peerani, Gastón Agustín Primo, Zhi Yuan Lin, Sacha Hu, Aston Martin Crawley
-
Patent number: 11834520Abstract: This disclosure features structurally-stabilized and/or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the treatment of BFL-1- and/or MCL-1-expressing or -dependent cancers or diseases of cellular excess (e.g., autoimmune or inflammatory conditions). Also provided are combination therapies comprising such structurally-stabilized and/or cysteine-reactive peptides and inhibitors of the DNA damage response pathway, such as an ATM kinase inhibitor, ATR kinase inhibitor, CHK1/2 inhibitor, or PARP inhibitor; or an inhibitor of MCL-1, or a selective inhibitor of BCL-2, or an inhibitor of BCL-2/BCL-XL, for the treatment of BFL-1-expressing or -dependent cancers (e.g., AML), BFL-1 and MCL-1-expressing or -dependent cancers, or diseases of cellular excess (e.g., autoimmune or inflammatory conditions).Type: GrantFiled: December 13, 2018Date of Patent: December 5, 2023Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Gregory H. Bird, Rachel Guerra, Edward Harvey
-
Patent number: 11834677Abstract: Methods of expanding a natural killer (NK) cell fraction for transplantation into a subject are provided, and particularly, methods for providing transplantable NK cell fractions and protocols for their use, which can be employed for applications in cell transplants and infusions for treatment of cancer and other disease.Type: GrantFiled: September 27, 2018Date of Patent: December 5, 2023Inventor: Tony Peled
-
Patent number: 11828757Abstract: Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.Type: GrantFiled: July 30, 2020Date of Patent: November 28, 2023Assignee: BioCardia, Inc.Inventors: Peter Altman, Cheryl Wong Po Foo
-
Patent number: 11827663Abstract: Disclosed are UAP inhibitors to inhibit glucose flux in the hexosamine biosynthetic pathway and methods of treating a disease using the inhibitors.Type: GrantFiled: December 18, 2020Date of Patent: November 28, 2023Assignee: The Johns Hopkins UniversityInventors: Kevin J. Yarema, Christopher T. Saeui, Alfredo Quinones-Hinojosa, Sagar Ramesh Shah
-
Patent number: 11813316Abstract: The invention is directed to a more efficient lentiviral vector comprising a nucleic acid sequence encoding a human ?-globin protein or a human ?-globin protein, which is oriented from 5? to 3? relative to the lentiviral genome. The invention also provides a composition and method utilizing the lentiviral vector.Type: GrantFiled: December 17, 2019Date of Patent: November 14, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Naoya Uchida, John F. Tisdale
-
Patent number: 11806072Abstract: Method and apparatus for treating peripheral olfactory dysfunction are described herein. One method may include introducing a treatment device into a nasal cavity of the patient, the treatment device having a proximal end, a distal end, an elongated shaft therebetween, and a treatment end effector disposed on or near the distal end. The distal end of the treatment device may be advanced into proximity of a cribriform plate within the nasal cavity and at least one olfactory neuron may be ablated through the cribriform plate via the treatment end effector to reduce at least one symptom of olfactory dysfunction.Type: GrantFiled: October 19, 2022Date of Patent: November 7, 2023Inventor: Dorna Hakimimehr
-
Patent number: 11793813Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.Type: GrantFiled: June 8, 2022Date of Patent: October 24, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Feng-Jing Chen, Steven L Krill
-
Patent number: 11795220Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.Type: GrantFiled: June 17, 2020Date of Patent: October 24, 2023Assignee: COMPUGEN LTD.Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
-
Patent number: 11786545Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5?-triphosphate and/or at least one 5?-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject.Type: GrantFiled: March 30, 2022Date of Patent: October 17, 2023Assignee: Yale UniversityInventors: Anna Marie Pyle, Akiko Iwasaki, Tianyang Mao
-
Patent number: 11788083Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.Type: GrantFiled: June 19, 2017Date of Patent: October 17, 2023Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng Zhang, Omar O. Abudayyeh, Jonathan Gootenberg, Eric S. Lander
-
Patent number: 11791043Abstract: A method is provided for prognosing a risk in a patient diagnosed with a premalignant lesion of the breast of the lesion progressing to breast cancer, the method comprising: providing a tissue sample of the premalignant lesion; detecting one or more variants of Osteopontin (OPN) selected from OPN-a, OPN-b and OPN-c in the sample; and prognosing an elevated risk of the lesion progressing to breast cancer if OPN-b and/or OPN-c is detected and/or OPN-a is elevated above normal levels in the tissue sample. Methods of assessing risk of death from breast cancer, methods of treatment, and kits for prognosis are also provided herein.Type: GrantFiled: September 6, 2018Date of Patent: October 17, 2023Assignee: University of CincinnatiInventor: Georg F. Weber
-
Patent number: 11781138Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.Type: GrantFiled: October 14, 2020Date of Patent: October 10, 2023Assignee: Aro Biotherapeutics CompanyInventors: Russell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin